Viridian Therapeutics to Participate in Upcoming May Investor Conferences
May 10 2024 - 8:00AM
Business Wire
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that senior management will participate in the following
upcoming investor conferences in May:
- 2024 RBCCM Global Healthcare Conference
(New York, NY): Presentation on Tuesday, May 14, 2024, at
8:30 a.m. ET.
- BofA Securities 2024 Health Care
Conference (Las Vegas, NV): Presentation on Wednesday, May
15, 2024, at 4:35 p.m. PT.
A live webcast of each presentation can be accessed under
“Events and Presentations” on the Investors section of the Viridian
website at viridiantherapeutics.com. A replay of the webcasts will
be available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and protein engineering enables the development of
differentiated therapeutic candidates for previously validated drug
targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting a pivotal program for VRDN-001, including two global
phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate its
efficacy and safety in patients with active and chronic TED.
Viridian’s goal is to advance VRDN-001 as a potential best-in-class
intravenous therapy followed by VRDN-003 as a potential
best-in-class subcutaneous therapy for the treatment of TED.
In addition to its TED portfolio, Viridian is advancing a novel
portfolio of neonatal Fc receptor (FcRn) inhibitors, including
VRDN-006 and VRDN-008, which has the potential to be developed in
multiple autoimmune diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240510199739/en/
Louisa Stone, 617-272-4604 Manager, Investor Relations
IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Apr 2024 to May 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From May 2023 to May 2024